Pricing
  1. JP-listed companies
  2. ReproCELL Incorporated
  3. Financials
  4. Pretax margin (%)

ReproCELL Incorporated【JP:4978】

Market cap
¥16B
P/E ratio
-27.8x
Reprocell develops iPS cell technology for research and medical applications, providing lab products and services to pharmaceutical companies while advancing regenerative medicine treatments.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndPretax margin (%) YoY (%)
Mar 31, 20251.5-8.67%
Mar 31, 20241.7-140.87%
Mar 31, 2023-4.1-82.15%
Mar 31, 2022-22.7-62.97%
Mar 31, 2021-61.3-17.50%
Mar 31, 2020-74.3+29.01%
Mar 31, 2019-57.6-42.93%
Mar 31, 2018-100.9+35.50%
Mar 31, 2017-74.5-32.08%
Mar 31, 2016-109.7+36.12%
Mar 31, 2015-80.6+179.57%
Mar 31, 2014-28.8-1796.14%
Mar 31, 20131.7-125.72%
Mar 31, 2012-6.6

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)